Effect of the COVID‐19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation

Author:

Mariottini Alice12,Lotti Antonio1,Innocenti Chiara3,Repice Anna Maria2,Nozzoli Chiara3,Boncompagni Riccardo3,Fainardi Enrico45,Saccardi Riccardo3,Massacesi Luca12

Affiliation:

1. Department of Neurosciences, Drug and Child Health University of Florence Florence Italy

2. Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre Careggi University Hospital Florence Italy

3. Cell Therapy and Transfusion Medicine Unit Careggi University Hospital Florence Italy

4. Neuroradiology Unit Careggi University Hospital Florence Italy

5. Department of Experimental and Clinical Biomedical Sciences University of Florence Florence Italy

Abstract

AbstractBackground and purposeIt is still debated whether the COVID‐19 pandemic affected disease activity in people with autoimmune diseases, including multiple sclerosis (MS). The aim of this study, therefore, was to explore the impact of COVID‐19 in people with MS (pwMS) not receiving continuative disease‐modifying therapy (DMT) after previous treatment with autologous hematopoietic stem cell transplantation (AHSCT).Materials and methodsWe included pwMS treated with AHSCT who were in disease remission without receiving DMTs during the pandemic and who were followed up at our centre during the study period. Data on SARS‐CoV‐2 infection and vaccination were recorded, with details of adverse events and clinical‐radiological disease activity.ResultsA total of 36 pwMS (31 females; 86%) were included, of whom 23 (64%) had relapsing‐remitting (RR‐MS) and 13 had secondary progressive MS (SP‐MS). Thirty‐three pwMS (92%) received anti‐SARS‐CoV‐2 mRNA vaccines. Thirteen patients (36%) developed mild to moderate COVID‐19 a median (range) of 58 (4–224) months after AHSCT; seven (54%) of these patients were not yet vaccinated. Transient neurological symptoms after vaccination or infection were reported in 9% and 36% of the patients, respectively. The rate of new inflammatory events (relapses or asymptomatic magnetic resonance imaging [MRI] activity) after AHSCT increased from 0.006 (one asymptomatic new lesion/159 patient‐years) before the pandemic to 0.083 (five relapses plus two cases of asymptomatic MRI activity/84 patient‐years) since the pandemic start (p = 0.004).ConclusionsPeople with MS with a history of highly active disease, who are untreated or receiving moderate‐efficacy DMTs might be more vulnerable to disease reactivation, possibly elicited by exogenous triggers. Careful monitoring and further investigation are warranted to ascertain whether special precautions are needed in these cases.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3